Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
TCR2 Therapeutics Inc. TCRR
$1.93
-$0.03 (-1.53%)
На 18:01, 12 мая 2023
+159.07%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
76918632.00000000
-
week52high
3.88
-
week52low
0.82
-
Revenue
0
-
P/E TTM
0
-
Beta
1.92688600
-
EPS
-4.09000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 19 мая 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 23 мар 2022 г. |
| Goldman Sachs | Neutral | Buy | 19 янв 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 13 янв 2022 г. |
| SVB Leerink | Market Perform | Market Perform | 10 ноя 2021 г. |
| SVB Leerink | Market Perform | Market Perform | 08 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 21 ноя 2022 г. |
| Piper Sandler | Overweight | Overweight | 06 янв 2023 г. |
| EF Hutton | Hold | 05 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Cardama Alfonso Quintas | A | 11775 | 11775 | 15 дек 2022 г. |
| Cardama Alfonso Quintas | A | 70649 | 70649 | 15 дек 2022 г. |
| Menzel Garry E | A | 39681 | 39681 | 15 дек 2022 г. |
| Menzel Garry E | A | 238008 | 238008 | 15 дек 2022 г. |
| Sullivan Eric | A | 6804 | 6804 | 15 дек 2022 г. |
| Sullivan Eric | A | 40820 | 40820 | 15 дек 2022 г. |
| Allen Andrew R | A | 16800 | 16800 | 15 дек 2022 г. |
| Olagunju Peter | A | 16354 | 16354 | 15 дек 2022 г. |
| Olagunju Peter | A | 98124 | 98124 | 15 дек 2022 г. |
| Justice Angela | A | 13083 | 13083 | 15 дек 2022 г. |
Новостная лента
5 Penny Stocks To Buy According To Analysts, Targets Up To 952%
PennyStocks
07 мар 2023 г. в 11:35
Penny stocks to buy according to analysts in 2023 The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 952% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?
InvestorPlace
06 мар 2023 г. в 10:45
TCR2 Therapeutics (NASDAQ: TCRR ) stock is jumping more than 30% in early trading on March 6 after the company agreed to merge with Adaptimmune (NASDAQ: ADAP ). Meanwhile, Adaptimmune is falling more than 15%.
TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path
Seeking Alpha
15 февр 2023 г. в 06:00
Reprioritization of pipeline sees 40% reduction of workforce with enough cash to fund pipeline into early 2025. Proof of concept established using gavo-cel for the treatment of patients with mesothelin tumors; Focus shift more towards targeting ovarian cancer patients with expected data 2nd half of 2023.
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
GlobeNewsWire
08 февр 2023 г. в 06:45
CAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will present a company update at the SVB Securities Global Biopharma Conference (virtual) on Tuesday, February 14, 2023 at 1:00 PM ET.
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
GlobeNewsWire
23 ноя 2022 г. в 06:45
CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference on Tuesday, November 29 at 2:00PM E.T.